Dapoxetine is indicated for the treatment of premature ejaculation (PE) in adult men aged 18 to 64 years. Dapoxetine should only be prescribed to patients who meet all the following criteria:
• An intravaginal ejaculatory latency time (IELT) of less than two minutes; and
• Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and
• Marked personal distress or interpersonal difficulty as a consequence of PE; and
• Poor control over ejaculation; and
• A history of premature ejaculation in the majority of intercourse attempts over the prior 6 months.
Dapoxetine should be administered only as on-demand treatment before anticipated sexual activity. Dapoxetine should not be prescribed to delay ejaculation in men who have not been diagnosed with PE
Dapoxetine is indicated for the treatment of premature ejaculation (PE) in adult men aged 18 to 64 years. Dapoxetine should only be prescribed to patients who meet all the following criteria:
• An intravaginal ejaculatory latency time (IELT) of less than two minutes; and
• Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and
• Marked personal distress or interpersonal difficulty as a consequence of PE; and
• Poor control over ejaculation; and
• A history of premature ejaculation in the majority of intercourse attempts over the prior 6 months.
Dapoxetine should be administered only as on-demand treatment before anticipated sexual activity. Dapoxetine should not be prescribed to delay ejaculation in men who have not been diagnosed with PE
Sertraline is indicated for the treatment of:
Major depressive episodes.
Prevention of recurrence of major depressive episodes. Panic disorder, with or without agoraphobia.
Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years. Social anxiety disorder.
Post-traumatic stress disorder (PTSD).
Sertraline is indicated for the treatment of:
Major depressive episodes.
Prevention of recurrence of major depressive episodes. Panic disorder, with or without agoraphobia.
Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years. Social anxiety disorder.
Post-traumatic stress disorder (PTSD).
Myelodysplastic Syndromes (MDS)
Azacitidine is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Juvenile Myelomonocytic Leukemia (JMML)
Azacitidine is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML
Type 2 diabetes mellitus
Dapagliflozin is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
Heart failure
Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic kidney disease
Dapagliflozin is indicated in adults for the treatment of chronic kidney disease.
Eptifibatide is intended for use with acetylsalicylic acid and unfractionated heparin.
Eptifibatide is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.
Patients most likely to benefit from eptifibatide treatment are those at high risk of developing myocardial infarction within the first 3-4 days after of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty)
Melphalan Hydrochloride TBM is intended for the following indications:
·Melphalan at conventional intravenous dose, is indicated in the treatment of multiple myeloma and advanced ovarian cancer.
·Melphalan, at high intravenous dosage, is indicated, with or without haematopoietic stem cell transplantation, for the treatment of multiple myeloma and childhood neuroblastoma.
·Melphalan, administered by regional arterial perfusion, is indicated in the treatment of localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities.
Sodium Chloride 5% Eye Ointment is a hypertonicity preparation since it contains high concentration of Sodium chloride. It acts by drawing water out of the eye cornea.
Sodium Chloride 5% Eye Ointment is indicated to relief corneal edema temporarily in in inflammation or chemosis.
